Health Care·Biotechnology·$5.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.51 | N/A | -9.68% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.51 | N/A | -9.68% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management conveyed a cautious outlook, recognizing difficulties while maintaining a commitment to their strategic objectives.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term goals despite current setbacks.
Xenon Pharmaceutical's earnings report shows a miss on EPS, which contributed to a 1.91% decline in stock price. The lack of revenue figures and guidance indicates uncertainty in their financial outlook. Investors may be concerned about the company's current challenges and future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MONOLITHIC PWR SYS I
Oct 31, 2016